Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CombinatoRx Singapore Pte Ltd.

Latest From CombinatoRx Singapore Pte Ltd.

STOCKWATCH: Name, Platform; Time of death, December 2013

They only come out towards the end of an IPO window. After investors have snapped up all the preclinical or Phase I-stage drug development companies and the venture capitalists are scratching around their portfolios to off-load risk and negative cash flows onto the public markets from investments that weren't formed five minutes ago, then we see the platform companies.

Cardiovascular Cancer

Zalicus slumps as another lead candidate bites the dust

Zalicus' lead drug candidate Z160 has failed in two Phase II chronic pain trials, prompting the company to terminate its development. The news sent the company's share price into a nose dive. It closed 72% down at $1.30 on the news (11 November).

Orthopedics Neurology

Zalicus shifts focus to pain after lead project Synavive fails in arthritis

It's on to plan B for Zalicus, which saw its stock price drop 43.2% to $0.79 per share on 10 September after the company announced that it is dropping development of its lead drug candidate, Synavive, due to a lack of clinically meaningful benefit for rheumatoid arthritis (RA) patients in a Phase IIb study.

Immune Disorders Orthopedics

Third Rock's $40M bet on Blueprint's rapid quest to personalise cancer therapies

"Our vision is to transform certain cancers into manageable conditions." So says, founding president and CEO of Blueprint Medicines, Chris Varma.

See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools